论文部分内容阅读
目的:探讨熊去氧胆酸(UDCA)治疗妊娠期肝内胆汁淤积症(ICP)对胎盘多药耐药相关蛋白(MRP)的影响。方法:实验分为ICP未治疗组、ICP治疗组及正常妊娠组,测定三组孕妇分娩前及分娩后血清总胆汁酸(TBA)、甘胆酸(CG);逆转录实时荧光定量PCR和免疫组化法检测三组胎盘多药耐药相关蛋白(MRP1、MRP2、MRP5)的表达。结果:UDCA治疗显著降低TBA及CG水平(P<0.001);UDCA治疗显著下调ICP孕妇胎盘中MRP1 mRNA和蛋白的表达,显著上调胎盘MRP2、MRP5 mRNA和蛋白的表达(P<0.05)。结论:熊去氧胆酸可能通过调节胎盘多药耐药相关蛋白影响胆汁酸的转运来治疗妊娠期肝内胆汁淤积症。
Objective: To investigate the effect of ursodeoxycholic acid (UDCA) on placental multidrug resistance-associated protein (MRP) in treating intrahepatic cholestasis of pregnancy (ICP). Methods: The experiment was divided into ICP untreated group, ICP treatment group and normal pregnancy group. Serum total bile acid (TBA) and glycocholic acid (CG) were measured before delivery and after delivery in pregnant women. RT-PCR and immunofluorescence The expression of multidrug resistance-related proteins (MRP1, MRP2, MRP5) in three groups of placenta were detected by histochemical method. Results: UDCA treatment significantly reduced TBA and CG levels (P <0.001). UDCA treatment significantly down-regulated the expression of MRP1 mRNA and protein in the placenta of pregnant women with ICP, significantly up-regulated the mRNA and protein expression of MRP2 and MRP5 in placenta (P <0.05). Conclusion: Ursodeoxycholic acid may treat intrahepatic cholestasis of pregnancy by regulating the transport of bile acid by placental multidrug resistance-related proteins.